(Q42269134)

English

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results

scientific article published on 26 March 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Keikawus Arastéh

7

object named as

Keikawus Arastéh

0 references

author name string

Joel E Gallant

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ellen Koenig

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jaime Andrade-Villanueva

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ploenchan Chetchotisakd

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Edwin DeJesus

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Francisco Antunes

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Keikawus Arastéh

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Graeme Moyle

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Giuliano Rizzardini

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jan Fehr

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Yapei Liu

11

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Lijie Zhong

12

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Christian Callebaut

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Javier Szwarcberg

14

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Martin S Rhee

15

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Andrew K Cheng

16

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

26 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

208

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

32-39

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT122

21 January 2018

Identifiers

10.1093/INFDIS/JIT122

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42269134&oldid=1940743822"